Sionna Therapeutics (SION) Q2 2026 earnings summary

Executive summary

• Focused on developing novel therapies for cystic fibrosis by stabilizing the CFTR protein's NBD1 domain, with two key clinical trials on track for topline data in summer 2026.

• Completed Phase 1 trials for lead NBD1 stabilizers (SION-719, SION-451) with positive safety and PK results; Phase 2a and dual combination trials underway.

• Presented new and encore clinical/nonclinical data at major cystic fibrosis conferences, highlighting the potential of NBD1 stabilizers.

• No product revenue to date; operations funded by equity offerings and IPO proceeds.

Financial highlights

• Net loss of $29.9M for Q2 2026, up from $18.1M in Q2 2025; net loss of $56.7M for the six months ended June 30, 2026, up from $34.6M year-over-year.

• Operating expenses rose to $32.5M for Q2 2026 (up $10.6M year-over-year) and $62.1M for the six months (up $20.5M year-over-year), driven by increased R&D and G&A costs.

• Research and development expenses rose to $21.9M for Q2 2026, up from $15.4M in Q2 2025; G&A expenses increased to $10.0M from $5.0M year-over-year.

• Cash, cash equivalents, and marketable securities totaled $268.3M as of June 30, 2026.

• Accumulated deficit reached $313.0M as of June 30, 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations into 2028, but substantial additional capital will be needed for future development and commercialization.

• Topline data from ongoing Phase 2a and dual combination trials anticipated in summer 2026.